Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Hepion Pharmaceuticals ( (HEPA) ).
On May 9, 2025, Hepion Pharmaceuticals received a notice from Nasdaq indicating the delisting of its shares due to non-compliance with listing standards, specifically failing to maintain a minimum bid price and being considered a public shell. Consequently, trading of Hepion’s common stock on Nasdaq will be suspended starting May 13, 2025, with expectations to be quoted on the OTC Markets Group. This development follows Hepion’s recent strategic shift, including a licensing agreement with New Day Diagnostics LLC for diagnostic tests, marking a significant change in its business operations and market focus.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company that has transitioned to developing and distributing diagnostic tests for diseases such as celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori, and hepatocellular carcinoma (HCC). The company was previously focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
Average Trading Volume: 4,870,832
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.28M
Find detailed analytics on HEPA stock on TipRanks’ Stock Analysis page.